Literature DB >> 2063957

Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease.

A Barral1, D Pedral-Sampaio, G Grimaldi Júnior, H Momen, D McMahon-Pratt, A Ribeiro de Jesus, R Almeida, R Badaro, M Barral-Netto, E M Carvalho.   

Abstract

One hundred fourteen Leishmania isolates from patients with different clinical forms of leishmaniasis in the State of Bahia, Brazil, were characterized by indirect radioimmune binding assay using specific monoclonal antibodies (serodeme analysis). Seventy-five of these isolates were also analyzed by enzyme electrophoresis, based on 11 enzyme loci; parasite species were compared, according to their characteristic zymodemes, to those of WHO Leishmania reference strains. All isolates could be classified into one of three species: Leishmania amazonensis (n = 40), L. braziliensis (n = 39) or L. chagasi (n = 35). The most interesting information obtained from this study is the realization that L. amazonensis is capable of producing a wide spectrum of disease in humans. Infection with this parasite was associated with many different clinical presentations, including cutaneous leishmaniasis [CL] (20/49 cases), mucocutaneous leishmaniasis [MCL] (5/13 cases) and, of special note, visceral leishmaniasis [VL] (11/46 cases), as well as four cases of post kalaazar dermal leishmaniasis [PKDL]. In situ tissue parasite characterization, by immunoperoxidase assay and employing anti-L. amazonensis amastigote monoclonal antibodies, confirmed the infection with this species in two cases of CL, one case of DCL, one case of MCL and one case of PKDL. Our results also demonstrate the difficulty of parasite differentiation based on clinical grounds, since at least L. amazonensis infection can be associated with all types of leishmanial diseases, and different Leishmania species may be associated with indistinguishable clinical presentations. Since leishmanial parasites may vary in their biological behavior or in their response to treatment, it is important that their identification be made by reliable methods.

Entities:  

Mesh:

Year:  1991        PMID: 2063957     DOI: 10.4269/ajtmh.1991.44.536

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  83 in total

1.  Leishmania infection impairs beta 1-integrin function and chemokine receptor expression in mononuclear phagocytes.

Authors:  Nathanael F Pinheiro; Micely D R Hermida; Mariana P Macedo; José Mengel; Andre Bafica; Washington L C dos-Santos
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species.

Authors:  Roger Adrian Figueroa; Leyder Elena Lozano; Ibeth Cristina Romero; Maria Teresa Cardona; Martin Prager; Robinson Pacheco; Yira Rosalba Diaz; Jair Alexander Tellez; Nancy Gore Saravia
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

3.  Vector Competence of Lutzomyia cruzi Naturally Demonstrated for Leishmania infantum and Suspected for Leishmania amazonensis.

Authors:  Everton Falcão de Oliveira; Elisa Teruya Oshiro; Wagner Souza Fernandes; Alda Maria Teixeira Ferreira; Alessandra Gutierrez de Oliveira; Eunice Aparecida Bianchi Galati
Journal:  Am J Trop Med Hyg       Date:  2016-11-14       Impact factor: 2.345

4.  The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil.

Authors:  Rajendranath Ramasawmy; Eliane Menezes; Andrea Magalhães; Joyce Oliveira; Léa Castellucci; Roque Almeida; Maria Elisa A Rosa; Luiz Henrique Guimarães; Marcus Lessa; Elza Noronha; Mary E Wilson; Sarra E Jamieson; Jorge Kalil; Jenefer M Blackwell; Edgar M Carvalho; Amélia Ribeiro de Jesus
Journal:  Infect Genet Evol       Date:  2010-04-27       Impact factor: 3.342

5.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

6.  Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation.

Authors:  L R V Antonelli; W O Dutra; R P Almeida; O Bacellar; K J Gollob
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 7.  Leishmaniasis treatment--a challenge that remains: a review.

Authors:  Dilvani O Santos; Carlos E R Coutinho; Maria F Madeira; Carolina G Bottino; Rodrigo T Vieira; Samara B Nascimento; Alice Bernardino; Saulo C Bourguignon; Suzana Corte-Real; Rosa T Pinho; Carlos Rangel Rodrigues; Helena C Castro
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

8.  Sand fly saliva enhances Leishmania amazonensis infection by modulating interleukin-10 production.

Authors:  Nilufer B Norsworthy; Jiaren Sun; Dia Elnaiem; Gregory Lanzaro; Lynn Soong
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 9.  Molecular epidemiology for vector research on leishmaniasis.

Authors:  Hirotomo Kato; Eduardo A Gomez; Abraham G Cáceres; Hiroshi Uezato; Tatsuyuki Mimori; Yoshihisa Hashiguchi
Journal:  Int J Environ Res Public Health       Date:  2010-03-05       Impact factor: 3.390

10.  The Leishmania amazonensis TRF (TTAGGG repeat-binding factor) homologue binds and co-localizes with telomeres.

Authors:  Marcelo S da Silva; Arina M Perez; Rita de Cássia V da Silveira; Camila E de Moraes; Jair L Siqueira-Neto; Lucio de H Freitas; Maria Isabel N Cano
Journal:  BMC Microbiol       Date:  2010-05-07       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.